Glaucoma Clinical Trial
— PROVEOfficial title:
A Prospective Analysis of Nerve Fiber Layer and Macular Changes After Pars Plana Vitrectomy
Verified date | February 2017 |
Source | Vanderbilt University Medical Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Since the introduction of vitrectomy in 1971, this procedure has become the third most
frequently performed ophthalmic surgery. Approximately 225,000 vitrectomies are performed
annually in the United States and indications continue to expand. Known long-term
complications of vitrectomy are relatively few and include retinal detachment and cataract
formation. Although much has been written in the literature concerning acute rises in
intraocular pressure (IOP) in the immediate postoperative period, there is surprisingly
little information on long term IOP outcomes after vitrectomy. A recent report by Chang
given at the LXII (62) Edward Jackson Memorial Lecture hypothesized a causal relationship
between vitrectomy and open-angle glaucoma (OAG) via oxidative stress exacerbated by removal
of the crystalline lens. A second report by Luk and colleagues reported similar conclusions
in a modified cohort. Both studies, were retrospective in nature and did not perform
baseline evaluations to exclude pre-existing glaucoma. Furthermore neither study accounted
for natural history. Finally, our analysis has not reproduced similar results.
The primary purpose of this study is to analyze the full spectrum of optic nerve and macular
changes between vitrectomized study eyes and their non-vitrectomized fellow eyes to control
for natural history. Baseline evaluations will include examination by fellowship trained
retina and glaucoma specialists, fundus photography, autofluorescence, optical coherence
tomography (macula and optic nerve) and automated visual field testing. At 3 month then
annually for 5 years after vitrectomy surgery, the cohort will undergo similar evaluation.
Status | Completed |
Enrollment | 45 |
Est. completion date | January 24, 2017 |
Est. primary completion date | January 24, 2017 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Able to consent and comply for the duration of the study and imaging studies - Media clarity sufficient for imaging studies - No previous treatment or surgery that might confound study results in the study or fellow eye - Pars plana vitrectomy (PPV) indicated for epiretinal membrane (ERM), macular hole (MH), vitreo-macular traction (VMT), and vitreous hemorrhage (VH) Exclusion Criteria: - Unable to consent and/or comply for the duration of the study and imaging studies - History of the following conditions: Glaucoma or associated conditions, visual field defects, uveitis, age-related macular degeneration (ARMD), prior PPV for retinal detachment, retained lens or dislocated intraocular lens - Contralateral eye status post PPV or with advanced eye disease serious enough to warrant future PPV - Contralateral eye with condition that may result in choroidal neovascular membrane |
Country | Name | City | State |
---|---|---|---|
United States | Vanderbilt Eye Institute | Nashville | Tennessee |
Lead Sponsor | Collaborator |
---|---|
Vanderbilt University |
United States,
Chang S. LXII Edward Jackson lecture: open angle glaucoma after vitrectomy. Am J Ophthalmol. 2006 Jun;141(6):1033-1043. — View Citation
Luk FO, Kwok AK, Lai TY, Lam DS. Presence of crystalline lens as a protective factor for the late development of open angle glaucoma after vitrectomy. Retina. 2009 Feb;29(2):218-24. doi: 10.1097/IAE.0b013e31818ba9ca. — View Citation
Machemer R, Buettner H, Norton EW, Parel JM. Vitrectomy: a pars plana approach. Trans Am Acad Ophthalmol Otolaryngol. 1971 Jul-Aug;75(4):813-20. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Nerve fiber layer and macular changes after vitrectomy | To determine the incidence of nerve fiber layer (NFL) and macular changes after pars plana vitrectomy, characterize their extent and quality, and determine pre-disposing risk factors. | 3 month and annually for 5 years after surgery | |
Secondary | Visual field defects | To characterize long-term functional consequences of NFL or macular changes with regards to peripheral and central visual field defects after PPV. | 3 month and annually for 5 years after surgery | |
Secondary | Open-angle glaucoma | To determine the incidence of elevated intraocular pressure and open-angle glaucoma following vitrectomy. Enrolled patients will be screened at baseline to exclude pre-existing glaucoma and post-operative glaucoma screenings will be performed by fellowship trained glaucoma specialist. | 3 month and annually for 5 years after surgery |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06000865 -
Glaucoma Rehabilitation With Action viDeo Games and Exercise - GRADE
|
N/A | |
Recruiting |
NCT06278597 -
Automatic Evaluation of the Anterior Chamber Angle Width by a New Non-contact Optical Device
|
N/A | |
Active, not recruiting |
NCT04271709 -
Manhattan Vision Screening and Follow-Up Study (NYC-SIGHT)
|
N/A | |
Recruiting |
NCT03274024 -
The Asia Primary Tube Versus Trab (TVT) Study
|
N/A | |
Completed |
NCT04552964 -
Assessment of the Impact of an add-on and Its Smartphone Application on the Daily Management of Glaucoma
|
N/A | |
Recruiting |
NCT01957267 -
Functional and Structural Imaging for Glaucoma
|
||
Active, not recruiting |
NCT04624698 -
iStent Inject New Enrollment Post-Approval Study
|
N/A | |
Completed |
NCT04020705 -
The Efficacy of Citicoline in Eyedrops (OMK1) in Reducing the Progression of Glaucoma
|
N/A | |
Completed |
NCT03150160 -
Additive Effect of Twice-daily Brinzolamide 1%/Brimonidine 0.2%Combination as an Adjunctive Therapy to Travoprost in Patients With Normal Tension Glaucoma
|
Phase 4 | |
Not yet recruiting |
NCT05581498 -
Glaucoma Exercise as Medicine Study (GEMS).
|
N/A | |
Recruiting |
NCT02921568 -
Side-by-Side Comparison of P200TE and Spectral OCT/SLO on Diseased Eyes
|
N/A | |
Active, not recruiting |
NCT02901730 -
Clinical Study of LPI With Different Laser Wavelengths
|
N/A | |
Completed |
NCT02955849 -
A Trial of China Laser and Surgery Study Glaucoma in Rural China
|
Early Phase 1 | |
Recruiting |
NCT02554214 -
Pilot Clinical Trial on a New Adjustable Glaucoma Drainage Device
|
N/A | |
Recruiting |
NCT02471105 -
Investigation of IOP and Tolerability of Bimatoprost 0.01% and Tafluprost Unit Dose Preservative Free 15 Microgram/ml
|
Phase 4 | |
Active, not recruiting |
NCT02390284 -
Stop Retinal Ganglion Cell Dysfunction Study
|
Phase 3 | |
Completed |
NCT02653963 -
Triamcinolone for Ahmed Glaucoma Valve
|
N/A | |
Completed |
NCT02520674 -
Glaucoma Screening With Smartphone Ophthalmology
|
N/A | |
Completed |
NCT02246764 -
Study of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension
|
Phase 3 | |
Completed |
NCT02628223 -
180 Degree vs. 360 Degree Selective Laser Trabeculoplasty as Initial Therapy for Glaucoma
|
N/A |